Company profile: Friz Biochem
1.1 - Company Overview
Company description
- Provider of advanced electronic biochips and offerings integrating the complete workflow of molecular diagnostics; privately held, founded in October 2004 and based in Neuried near Munich.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Friz Biochem
MaxThera
HQ: United States
Website
- Description: Provider of biopharmaceutical research and development of new treatments for bacterial infections, especially those caused by drug-resistant bacteria.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MaxThera company profile →
Peptilogics
HQ: United States
Website
- Description: Provider of clinical-stage therapeutics enabled by a computational deep learning platform for peptide drug discovery. Offerings include PLG0206, an investigational antibiotic peptide candidate for treating periprosthetic joint infection in clinical trial, an AI platform to predict peptide design across targets, and an expanded access policy for patients not qualifying for trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Peptilogics company profile →
Atriva Therapeutics
HQ: Germany
Website
- Description: Provider of host-targeting antiviral therapies for respiratory viral infections. Its lead candidate, zapnometinib (ATR-002), is an orally available small molecule designed to inhibit viral replication and modulate immune response to treat severe RNA-virus infections. Completed a Phase I safety study; assessing efficacy and safety in a Phase II study in hospitalized severe COVID-19 and planning Phase II development for severe influenza.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Atriva Therapeutics company profile →
Abivax
HQ: France
Website
- Description: Provider of clinical-stage biotechnology therapies that mobilize the body's natural immune machinery to treat autoimmune diseases, viral infections, and cancer, including obefazimod for ulcerative colitis (Phase 3), planned Phase 2b for Crohn's disease, exploration as combination therapy for ulcerative colitis in preclinical studies, and nonclinical evaluation for additional chronic inflammatory indications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Abivax company profile →
Paratek Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies based on novel tetracycline chemistry, including NUZYRA, an FDA-approved tetracycline-class antibiotic for adults with CABP and ABSSSI caused by select susceptible microorganisms, and SEYSARA, an FDA-approved oral therapy for inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients aged 9 years and older.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Paratek Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Friz Biochem
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Friz Biochem
2.2 - Growth funds investing in similar companies to Friz Biochem
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Friz Biochem
4.2 - Public trading comparable groups for Friz Biochem
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →